Newlin Investment Company

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors for drug discovery and cellular biology research. The company creates Fluorogenic Activating Modules (FAMs) that enable accurate detection of cellular trafficking, facilitating high-throughput screening and subsequent analysis. Its offerings include single-chain antibody fragments that activate fluorescence in specially designed dyes, assays for receptor internalization, and fluorogenic sensor dyes. Sharp Edge Labs focuses on addressing monogenic diseases, trafficking defects, and patient-driven discovery, with specific programs aimed at correcting trafficking defects in conditions such as cystic fibrosis and Parkinson's disease, as well as addressing lysosomal storage disorders. Originally known as Sharp Edge Technologies, Inc., the company was incorporated in 2010.

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, that specializes in spatial intelligence software products designed for analyzing pathology tissue sections in cancer diagnosis. Founded in 2017, the company offers innovative solutions such as SpIntellx, which processes image data sets from various imaging platforms and reagents, and HistoMapr, a computational guide for pathologists. Additionally, TumorMapr is utilized to analyze the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. With a focus on Precision Pathology and Spatially Intelligent Biology, SpIntellx leverages unbiased spatial analytics powered by explainable AI to enhance understanding of complex cancer biology, thereby facilitating advancements in drug development, diagnostics, and treatment strategies.

C2Sense develops chemiresistive gas sensors for food and agriculture applications, monitoring fruit ripeness and meat/fish/poultry freshness. Its sensors detect ethylene and biogenic amines at low concentrations, helping reduce waste throughout the supply chain.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Sharp Edge Labs, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of biosensors for drug discovery and cellular biology research. The company creates Fluorogenic Activating Modules (FAMs) that enable accurate detection of cellular trafficking, facilitating high-throughput screening and subsequent analysis. Its offerings include single-chain antibody fragments that activate fluorescence in specially designed dyes, assays for receptor internalization, and fluorogenic sensor dyes. Sharp Edge Labs focuses on addressing monogenic diseases, trafficking defects, and patient-driven discovery, with specific programs aimed at correcting trafficking defects in conditions such as cystic fibrosis and Parkinson's disease, as well as addressing lysosomal storage disorders. Originally known as Sharp Edge Technologies, Inc., the company was incorporated in 2010.

Machine Translation answers the need of today’s global business for high volume and high velocity content localization and enterprise translation. Safaba provides Enterprise Machine Translation solutions to the world’s leading global enterprises.

Liquid X specializes in developing and manufacturing functional electronics components using additive manufacturing techniques. The company partners with electronics industry manufacturers to create and print high-performance metal traces and films for applications such as sensors, heating elements, smart textiles, and thin-film solar cells. Liquid X's unique metallic conductive inks contain actual metal atoms, enabling low-temperature processing on a wide range of substrates, including paper, plastics, and organic materials.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Plextronics is a company that specializes in printed electronics, particularly in the development of organic light-emitting diode (OLED) displays and lighting. The company focuses on innovative technologies involving conductive inks and associated processes, which are essential for the mass production of printed electronic devices. Additionally, Plextronics is involved in the development of active layer technology for organic solar cells and plastic circuitry. By advancing these technologies, Plextronics aims to reduce production costs and enhance the feasibility of integrating printed electronics into various applications.